Anti-inflammatory effects of luteolin on experimental autoimmune thyroiditis in mice

Experimental and Therapeutic Medicine

Volumn 12, Issue 6, 2016, Pages 4049-4054

  Xia, Nan ^a   Chen, Gang ^b   Liu, Min ^a   Ye, Xiaozhen ^a   Pan, Yahui ^a   Ge, Jiuyu ^a   Mao, Yanting ^a   Wang, Hongwei ^a   Wang, Jian ^a   Xie, Sijing ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Autoimmune diseases; Hashimoto s thyroiditis; Luteolin; Signal transducer and activator of transcription 3

Indexed keywords

CYCLOOXYGENASE 2; DEXAMETHASONE; GAMMA INTERFERON; LUTEOLIN; STAT1 PROTEIN; STAT3 PROTEIN; THYROGLOBULIN ANTIBODY; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FEMALE; FREE THYROXINE INDEX; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MACROPHAGE CULTURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID FOLLICULAR CELL; THYROID GLAND; WESTERN BLOTTING;

EID: 84996528063     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3854     Document Type: Article

References (45)

1. McLeod DS and Cooper DS: The incidence and prevalence of thyroid autoimmunity. Endocrine 42: 252-265,2012.
2. Vaidya B and Pearce SH: Management of hypothyroidism in adults. BMJ 337: a801,2008.
3. Caturegli P,De Remigis A and Rose NR: Hashimoto thyroiditis: Clinical and diagnostic criteria. Autoimmun Rev 13: 391-397,2014.
4. Chistiakov DA: Immunogenetics of Hashimoto’s thyroiditis. J Autoimmune Dis 2: 1,2005.
5. McLachlan SM and Rapoport B: Autoimmune hypothyroidism: T cells caught in the act. Nat Med 10: 895-896,2004.
6. Quaratino S,Badami E,Pang YY,Bartok I,Dyson J,Kioussis D,Londei M and Maiuri L: Degenerate self-reactive human T-cell receptor causes spontaneous autoimmune disease in mice. Nat Med 10: 920-926,2004.
7. Saitoh O and Nagayama Y: Regulation of Graves’ hyperthyroidism with naturally occurring CD4+ CD25+ regulatory T cells in a mouse model. Endocrinology 147: 2417-2422,2006.
8. Nakano A,Watanabe M,Iida T,Kuroda S,Matsuzuka F,Miyauchi A and Iwatani Y. Apoptosis-induced decrease of intrathyroidal CD4+ CD25+ regulatory T cells in autoimmune thyroid diseases. Thyroid 17: 25-31,2007.
9. Wang SH and Baker JR: The role of apoptosis in thyroid autoimmunity. Thyroid 17: 975-979,2007.
10. Shi Y,Wang H,Su Z,Chen J,Xue Y,Wang S,Xue Y,He Z,Yang H,Zhou C,et al: Differentiation imbalance of Th1/Th17 in peripheral blood mononuclear cells might contribute to pathogenesis of Hashimoto’s thyroiditis. Scand J Immunol 72: 250-255,2010.
11. Li D,Cai W,Gu R,Zhang Y,Zhang H,Tang K,Xu P,Katirai F,Shi W,Wang L,et al: Th17 cell plays a role in the pathogenesis of Hashimoto’s thyroiditis in patients. Clin Immunol 149: 411-420,2013.
12. Zhu C,Ma J,Liu Y,Tong J,Tian J,Chen J,Tang X,Xu H,Lu L and Wang S: Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. J Clin Endocrinol Metab 97: 943-950,2012.
13. Harris TJ,Grosso JF,Yen HR,Xin H,Kortylewski M,Albesiano E,Hipkiss EL,Getnet D,Goldberg MV,Maris CH,et al: Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 179: 4313-4317,2007.
14. Chaudhry A,Rudra D,Treuting P,Samstein RM,Liang Y,Kas A and Rudensky AY: CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326: 986-991,2009.
15. Durant L,Watford WT,Ramos HL,Laurence A,Vahedi G,Wei L,Takahashi H,Sun HW,Kanno Y,Powrie F and O’Shea JJ: Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32: 605-615,2010.
16. Kim HP,Son KH,Chang HW and Kang SS: Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci 96: 229-245,2004.
17. López-Lázaro M: Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 9: 31-59,2009.
18. Xagorari A,Papapetropoulos A,Mauromatis A,Economou M,Fotsis T and Roussos C: Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther 296: 181-197,2001.
19. Kritas SK,Saggini A,Varvara G,Murmura G,Caraffa A,Antinolfi P,Toniato E,Pantalone A,Neri G,Frydas S,et al: Luteolin inhibits mast cell-mediated allergic inflammation. J Biol Regul Homeost Agents 27: 955-959,2013.
20. Ziyan L,Yongmei Z,Nan Z,Ning T and Baolin L: Evaluation of the anti-inflammatory activity of luteolin in experimental animal models. Planta Med 73: 221-226,2007.
21. Selvendiran K,Koga H,Ueno T,Yoshida T,Maeyama M,Torimura T,Yano H,Kojiro M and Sata M: Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: An implication for the antitumor potential of flavonoids. Cancer Res 66: 4826-4834,2006.
22. Parker-Athill E,Luo D,Bailey A,Giunta B,Tian J,Shytle RD,Murphy T,Legradi G and Tan J: Flavonoids,a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J Neuroimmunol 217: 20-27,2009.
23. Rezai-Zadeh K,Ehrhart J,Bai Y,Sanberg PR,Bickford P,Tan J and Shytle RD: Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. J Neuroinflammation 5: 41,2008.
24. Theoharides TC: Luteolin as a therapeutic option for multiple sclerosis. J Neuroinflammation 6: 29,2009.
25. Theoharides TC,Kempuraj D and Iliopoulou BP: Mast cells,T cells and inhibition by luteolin: Implications for the pathogenesis and treatment of multiple sclerosis. Adv Exp Med Biol 601: 423-430,2007.
26. Beeton C,Pennington MW,Wulff H,Singh S,Nugent D,Crossley G,Khaytin I,Calabresi PA,Chen CY,Gutman GA and Chandy KG: Targeting effector memory T cells with a selective peptide inhibitor of Kv1. 3 channels for therapy of autoimmune diseases. Mol Pharmacol 67: 1369-1381,2005.
27. Takeda K,Kaisho T,Yoshida N,Takeda J,Kishimoto T and Akira S: Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: Generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 161: 4652-4660,1998.
28. McLoughlin RM,Jenkins BJ,Grail D,Williams AS,Fielding CA,Parker CR,Ernst M,Topley N and Jones SA: IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci USA 102: 9589-9594,2005.
29. Zhou L,Ivanov II,Spolski R,Min R,Shenderov K,Egawa T,Levy DE,Leonard WJ and Littman DR: IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8: 967-974,2007.
30. Kimura A and Kishimoto T: IL-6: Regulator of Treg/Th17 balance. Eur J Immunol 40: 1830-1835,2010.
31. Nishihara M,Ogura H,Ueda N,Tsuruoka M,Kitabayashi C,Tsuji F,Aono H,Ishihara K,Huseby E,Betz UA,et al: IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int Immunol 19: 695-702,2007
32. Xiao L,Muhali FS,Cai TT,Song RH,Hu R,Shi XH,Jiang WJ,Li DF,He ST,Xu J and Zhang JA: Association of single-nucleotide polymorphisms in the STAT3 gene with autoimmune thyroid disease in Chinese individuals. Funct Integr Genomics 13: 455-461,2013.
33. Kotkowska A,Sewerynek E,Domańska D,Pastuszak-Lewandoska D and Brzeziańska E: Single nucleotide polymorphisms in the STAT3 gene influence AITD susceptibility,thyroid autoantibody levels and IL6 And IL17 secretion. Cell Mol Biol Lett 20: 88-101,2015.
34. Yan R,Yang J,Jiang P,Jin L,Ma J,Huang R,Ma N and Jiang F: Genetic variations in the SOCS3 gene in patients with Graves’ ophthalmopathy. J Clin Pathol 68: 448-452,2015.
35. Ajjan R and Weetman A: Cytokines in thyroid autoimmunity. Autoimmunity 36: 351-359,2003.
36. Park SJ,Nakagawa T,Kitamura H,Atsumi T,Kamon H,Sawa S,Kamimura D,Ueda N,Iwakura Y,Ishihara K,et al: IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173: 3844-3854,2004.
37. Weetman A,Bright-Thomas R and Freeman M: Regulation of interleukin-6 release by human thyrocytes. J Endocrinol 127: 357-361,1990.
38. Kotanidou A,Xagorari A,Bagli E,Kitsanta P,Fotsis T,Papapetropoulos A and Roussos C: Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. Am J Respir Crit Care Med 165: 818-823,2002.
39. Chen CY,Peng WH,Tsai KD and Hsu SL: Luteolin suppresses inflammation-associated gene expression by blocking NF-kappaB and AP-1 activation pathway in mouse alveolar macrophages. Life Sci 81: 1602-1614,2007.
40. Chen CC,Chow MP,Huang WC,Lin YC and Chang YJ: Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappaB: Structure-activity relationships. Mol Pharmacol 66: 683-693,2004.
41. Jang S,Kelley KW and Johnson RW: Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci USA 105: 7534-7539,2008.
42. Hutfless S,Matos P,Talor MV,Caturegli P and Rose NR: Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease. J Clin Endocrinol Metab 96: E1466-E1471,2011.
43. Maron R and Cohen IR: H-2K mutation controls immune response phenotype of autoimmune thyroiditis. Critical expression of mutant gene product in both thymus and thyroid glands. J Exp Med 152: 1115-1120,1980.
44. Einhorn J,Fagraeus A and Jonsson J: Thyroid antibodies after 131I treatment for hyperthyroidism. J Clin Endocrinol Metab 25: 1218-1224,1965.
45. Crofford LJ: COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol Suppl 49: 15-19,1997.